Keywords: تیازولیدیدئون; ACC; acetyl-CoA carboxylase; ADPH; adipophilin; Akt/PKB; protein kinase B; ALOX5; arachidonate 5-lipoxygenase; BTN1A1; butyrophilin subfamily 1 member a1; CIDEA; cell death-inducing DNA fragmentation factor α-like effector A; COX2; cyclooxygenase 2; DGAT
مقالات ISI تیازولیدیدئون (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: تیازولیدیدئون; AHR; aryl hydrocarbon receptor; ALD; alcoholic liver disease; BAs; bile acids; CAR; constitutive androstane receptor; CARM1; coactivator associated arginine methyltransferases 1; CBP/P300; CREB-binding protein/p300; CYP27A1/Cyp27a1; sterol 27α-hydroxylas
Keywords: تیازولیدیدئون; Anti-diabetic; PPARγ; Gene expression; Molecular docking; Thiazolidinedione; Pyrazole; ALP; alkaline phosphatase; ALT; alanine transaminase; AMPK; 5â² adenosine monophosphate-activated protein kinase is an enzyme; AST; aspartate transaminase; DMEM; Dulb
Keywords: تیازولیدیدئون; Thiazolidinedione; pH indicator; Pyrazole; Knoevenagel; Molecular modelling; Pancreatic lipase; Obesity; Orlistat;
Keywords: تیازولیدیدئون; Endometrial cancer; insulin-sensitizing agents; metformin; secretagogues; population-based; AMPK; activated protein kinase; ISA; insulin-sensitizing agent; PC; principal component; PCA; principal components analysis; PCOS; polycystic ovary syndrome; TZD;
Keywords: تیازولیدیدئون; DILI; drug induced liver injury; hES-HLCs; hepatocyte-like cells derived from human embryonic stem cells; APAP; acetaminophen; TZD; thiazolidinedione; TNF; tumor necrosis factor; ÎL; interleukin; IFN; interferon; PHHs; primary human hepatocytes; hES-DE;
Keywords: تیازولیدیدئون; PPAR; peroxisome proliferator-activated receptor; TZD; thiazolidinedione; ETYA; eicosatetraynoic acid; MTT; 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; AAALAC; American Association for the Accreditation of Laboratory Animal Care; Cer
Synthesis, molecular docking and anti-diabetic evaluation of 2,4-thiazolidinedione based amide derivatives
Keywords: تیازولیدیدئون; Antidiabetic; PPARγ; Thiazolidinedione; Molecular docking;
Keywords: تیازولیدیدئون; 5-HT(2B); 5-hydroxytryptamine 2B receptor; ACE; angiotensin-converting enzyme; AMPK; AMP-activated protein kinase; ARB; AT1R blocker; ASK1; apoptosis signal-regulating kinase 1; AT1R; angiotensin II type 1 receptor; ATX; autotaxin; BDL; bile duct ligation
Keywords: تیازولیدیدئون; AgRP; agouti-related peptide; ARC; arcuate; CRF; corticotropin releasing factor; DDC; dopa decarboxylase; GLUT1, 2, 3, and 8, respectively; glucose transporter 1, 2, 3, and 8; IR; insulin receptor; ICV; intracerebroventricular; NPY; neuropeptide Y; NPYr1,
Keywords: تیازولیدیدئون; Macrophage; Adipose; Inflammation; Obesity; Fibrosis; Insulin; AMPK; AMP-activated protein kinase; ATM; adipose tissue macrophages; CRP; C-reactive protein; DIO; diet-induced obesity; DPP-4; dipeptidyl peptidase-4; FFA; free fatty acids; GLP-1; glucagon-l
Keywords: تیازولیدیدئون; Wound healing; Insulin; Metformin; Sulfonylurea; Thiazolidinedione; DPP-4 inhibitor;
Keywords: تیازولیدیدئون; ALS; amyotrophic lateral sclerosis; ALT; alternative telomere lengthening mechanisms; ARIC; Atherosclerosis risk in communities; BP; blood pressure; CAD; coronary artery disease; CML; chronic myelogenous leukemia; CVD; cardiovascular disease; EC; endothel
Keywords: تیازولیدیدئون; AAD; antiarrhythmic drug; ACEi; angiotensin-converting enzyme inhibitor; AF; atrial fibrillation; AFFIRM; Atrial Fibrillation Follow-up Investigation of Rhythm Management; ARB; angiotensin receptor blocker; ARIC; Analysis of the Atherosclerosis Risk in Co
Keywords: تیازولیدیدئون; Benzimidazole; Thiazolidinedione; Apoptosis; MitoSOX; Annexin; Cell migration;
Keywords: تیازولیدیدئون; Glycated albumin; Glycosylated hemoglobin; Glucose lowering medication; Taiwan; Reference range; Atherosclerosis; Prevention; ALT; Alanine aminotransferase; XGI; Alpha-Glucosidase Inhibitor; BG; Biguanides; CRE; Creatinine; DM; Diabetes Mellitus; DPP-4; D
Keywords: تیازولیدیدئون; diabetes mellitus; insulin; metformin; psoriasis; thiazolidinedione; CI; confidence interval; ICD-9-CM; International Classification of Diseases, Ninth Revision, Clinical Modification; IL; interleukin; LHID; Longitudinal Health Insurance Dataset; NHIRD; N
Keywords: تیازولیدیدئون; Inflammation; Gliptin; GLP-1 receptor agonist; Metformin; Thiazolidinedione; Type 2 diabetes mellitus
Keywords: تیازولیدیدئون; calendar time-specific propensity score; conventional propensity score; diabetes mellitus; hospitalization; thiazolidinedione;
Keywords: تیازولیدیدئون; acne; androgenetic alopecia; combined oral contraceptive pills; cyproterone acetate; drospirenone; hirsutism; insulin-sensitizing drugs; polycystic ovary syndrome; spironolactone; cOCP; combined oral contraceptive pill; CPA; cyproterone acetate; EE; ethin
Keywords: تیازولیدیدئون; Adiponectin; Adipokine; Type 2 diabetes; Oligomerization; Electrophoresis; Thiazolidinedione;
Keywords: تیازولیدیدئون; Macrophage; dendritic cell; lipid; nuclear receptor; retinoid X receptor; retinoic acid receptor; peroxisome proliferator-associated receptor; liver X receptor; vitamin D receptor; rheumatoid arthritis; inflammatory bowel disease; systemic lupus erythemat
Keywords: تیازولیدیدئون; Diabetes mellitus type-2; Pioglitazone; Bladder carcinoma; Vascular complications; Thiazolidinedione
Pioglitazone and risk of bladder cancer in type 2 diabetes mellitus patients: A systematic literature review and meta-analysis of observational studies using real-world data
Keywords: تیازولیدیدئون; Bladder cancer; Pioglitazone; Thiazolidinedione; Systematic review; Meta-analysis;
The influence of peroxisome proliferator-activated receptor γ (PPARγ) ligands on cancer cell tumorigenicity
Keywords: تیازولیدیدئون; Cancer cells; PPARγ agonist; PPARγ antagonist; Therapeutic agents; Tumorigenicity; ACC; Acetyl-CoA carboxylase; AKR1B10; Alde-keto reductase 1B10; Alpha-ESA; Alpha-eleostreac acid; ACLY; ATP citrate lyase; BADGE; Bisphenol-A-diglycidyl-etter; CSCs; Canc
Structural and energetic quantum chemical investigations into how the bioactive thiazolidinedione and rhodanine scaffolds interact with cytosine to form part of DNA
Keywords: تیازولیدیدئون; Cytosine; Thiazolidinedione; Rhodanine; Hydrogen bond interaction; Dispersion corrections; Double hybrid functionals;
Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site
Keywords: تیازولیدیدئون; PPAR; peroxisome proliferator-activated receptor; LBD; ligand-binding domain; LBP; ligand-binding pocket; TZD; thiazolidinedione; Cdk5; cyclin-dependent kinase 5; SRC-1; steroid receptor coactivator-1; r.m.s.; root-mean-square; Crystal structure; Alternat
The effects of troglitazone on AMPK in HepG2 cells
Keywords: تیازولیدیدئون; AMPK; Troglitazone; Thiazolidinedione; HepG2; Diabetes; Ser485/491;
Conventional and microwave-assisted synthesis of new 1H-benzimidazole-thiazolidinedione derivatives: A potential anticancer scaffold
Keywords: تیازولیدیدئون; Benzimidazole; Thiazolidinedione; Cytotoxicity; Apoptosis; Microwave;
Importance of 5/6-aryl substitution on the pharmacological profile of 4ʹ-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1ʹ-biphenyl]-2-carboxylic acid derived PPARγ agonists
Keywords: تیازولیدیدئون; Peroxisome proliferator-activated receptor γ; Pharmacological profile; Coactivator recruitment; Transactivation assay; Molecular modeling; H; helix; LBD; ligand binding domain; PDB; Protein Data Bank; PPAR; peroxisome proliferator-activated receptor; PPR
Therapeutic journey of 2,4-thiazolidinediones as a versatile scaffold: An insight into structure activity relationship
Keywords: تیازولیدیدئون; Thiazolidinedione; PPARγ; Antihyperglycemic; Anticancer; Antimicrobial; AI-2; Auto inducer-2; ATP; Adenosine triphosphate; ALR; Aldose reductase; COX; Cyclooxygenase; EC50; Half maximal effective concentration; ED50; Median effective dose; FFAR1; Free fa
In silico design, chemical synthesis and toxicological evaluation of 1,3-thiazolidine-2,4-dione derivatives as PPARγ agonists
Keywords: تیازولیدیدئون; PPARγ agonists; Thiazolidinedione; In silico studies; Chemical synthesis; Acute toxicity;
Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present
Keywords: تیازولیدیدئون; Thiazolidinedione; Glitazones; Hypoglycemic; PPAR; Oxymethyl linker; Oxyethyl linker; Oxyethylamino linker; Rigid linker analogues;
PPARγ activation alters fatty acid composition in adipose triglyceride, in addition to proliferation of small adipocytes, in insulin resistant high-fat fed rats
Keywords: تیازولیدیدئون; Peroxisome proliferator-activated receptor γ; Fatty acid composition; Adipocyte size; Insulin resistance; Thiazolidinedione
PPARγ signaling and emerging opportunities for improved therapeutics
Keywords: تیازولیدیدئون; PPARγ; peroxisome proliferator-activated receptor gamma; TZD; thiazolidinedione; T2DM; type 2 diabetes mellitus; RGZ; rosiglitazone; 15d-PGJ2; 15-deoxy-D12,14-prostanglandin J2; PGC-1α; PPARγ co-activator-1α; RXR; retinoid X receptor; PPRE; peroxisome
Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome proliferator-activated receptor (PPAR) γ partial agonists
Keywords: تیازولیدیدئون; Method comparison; Docking; Pharmacophore modeling; Shape-based modeling; 2D-similarity based search; Peroxisome proliferator-activated gamma partial agonists; A; anion; Acc; accuracy; Ar; aromatic feature; AUC; area under the curve; C; cation; DMEM; Dulb
New telmisartan-derived PPARγ agonists: Impact of the 3D-binding mode on the pharmacological profile
Keywords: تیازولیدیدئون; PPARγ; Transactivation; Cytotoxicity; Binding mode; Molecular modeling; Amax; maximum intrinsic activity; BPO; benzoyl peroxide; DMEM; Dulbecco's modified Eagle medium; LBD; ligand binding domaine; mp; melting point; NBS; N-bromosuccinimide; PPAR; peroxi
Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists
Keywords: تیازولیدیدئون; Diabetes; PPARγ; FFAR1; Thiazolidinedione; Docking
The elusive endogenous adipogenic PPARγ agonists: Lining up the suspects
Keywords: تیازولیدیدئون; NO; nitric oxide; NO2; dioxide radical; O2; superoxide; ONO2â; Â peroxynitrite; 15-dPGJ2; 15-deoxy-Î12,14-prostaglandin J2; AA; arachidonic acid; ADH; alcohol dehydrogenase; AF-1; ligand-independent activation function; AF-2; ligand-dependent activatio
Knoevenagel condensation of aromatic bisulfite adducts with 2,4-thiazolidinedione in the presence of Lewis acid catalysts
Keywords: تیازولیدیدئون; Bisulfite adduct; Lewis acid; Knoevenagel condensation; Thiazolidinedione;
Continuation or discontinuation of pioglitazone when starting bedtime insulin in patients with poorly controlled type 2 diabetes in an inner-city population
Keywords: تیازولیدیدئون; Type 2 diabetes; Thiazolidinedione; Metformin; Pioglitazone; Sulfonylurea; HbA1c;
(2S)-7,4â²-dihydroxy-8-prenylflavan stimulates adipogenesis and glucose uptake through p38MAPK pathway in 3T3-L1 cells
Keywords: تیازولیدیدئون; (2S)-7,4â²-dihydroxy-8-prenylflavan; Adipogenesis; Glucose uptake; p38MAPK; Type 2 diabetes; aP2; aFABP, adipocyte fatty acid-binding protein; FFA; free fatty acid; GLUT4; glucose transporter type 4; IL; interleukin; TG; triglyceride; TZDs; thiazolidined
Circulating microRNA-320a and microRNA-486 predict thiazolidinedione response: Moving towards precision health for diabetes prevention
Keywords: تیازولیدیدئون; miR; microRNA; TZD; thiazolidinedione; HDL-c; high density lipoprotein cholesterol; RT-PCR; reverse transcription polymerase chain reaction; MicroRNA; Insulin resistance; Thiazolidinediones; Biomarkers; Precision health;
Effects of pioglitazone on cardiac and adipose tissue pathology in rats with metabolic syndrome
Keywords: تیازولیدیدئون; Metabolic syndrome; Thiazolidinedione; Cardiac remodeling; Inflammation; Adipose tissue; Glucose metabolism;
Pharmacological activation of PPAR gamma ameliorates vascular endothelial insulin resistance via a non-canonical PPAR gamma-dependent nuclear factor-kappa B trans-repression pathway
Keywords: تیازولیدیدئون; Ang II; angiotensin II; BMI; body mass index; CH; total cholesterol; DMEM; Dulbecco׳s modified Eagle׳s medium; eNOS; endothelial nitric oxide synthase; ET-1; endothelin-1; FBS; fetal bovine serum; FINS; fasting serum insulin; FPG; fasting plasma glucose
Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers
Keywords: تیازولیدیدئون; diabetes; drug-drug interaction; SGLT2 inhibitor; thiazolidinedione;
How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?
Keywords: تیازولیدیدئون; FDA actions; Medicaid; thiazolidinedione; type 2 diabetes;
Improved nonclinical pharmacokinetics and biodistribution of a new PPAR pan-agonist and COX inhibitor in nanocapsule formulation
Keywords: تیازولیدیدئون; Poly(d,l-lactide) (PubChem CID: 24877805); Poloxamer 188 or Polyoxyethylene-polyoxypropylene Block Copolymer (PubChem CID: 10129990); LYSO-7 or [(5Z)-5-[5-bromo-1H-indol-3-yl)methylene]-3-(4-chlorobenzyl)-thiazolidine-2,4-dione] (CAS Registry Number 15054
Cytotoxicity of thiazolidinedione-, oxazolidinedione- and pyrrolidinedione-ring containing compounds in HepG2 cells
Keywords: تیازولیدیدئون; Clustering; Cytotoxicity; HepG2 cells; Molecular fingerprints; Oxazolidinedione; Pyrrolidinedione; Succinimide; Thiazolidinedione; Troglitazone;
Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: Randomized controlled trial (PioRAGE)
Keywords: تیازولیدیدئون; Randomized clinical trial; Receptor for advanced glycation end-products (RAGE); Soluble RAGE; Thiazolidinedione;